Who is the CEO of KRM Ayurveda Ltd?
- Answer Field
-
The Managing Director and Promoter of KRM Ayurveda Ltd. is Dr. Puneet Dhawan.
KRM Ayurveda Ltd. operates in the AYUSH healthcare segment through a network of hospitals, clinics, teleconsultation services, and the manufacture of Ayurvedic and herbal products. Incorporated in 2019, the company began with a focus on kidney-related treatments and has since expanded its scope to cover other health conditions, including lifestyle and chronic disorders. Its operations span physical healthcare facilities as well as remote consultation and product distribution channels. The company’s activities are centred on integrating traditional Ayurvedic practices with structured treatment processes.
Investors who wish to apply for the KRM Ayurveda IPO can do so through the application process prescribed for public issues in India. Applications may be submitted using the ASBA facility through a bank account linked to a demat account, either via net banking or through a registered intermediary. Eligible investors can also apply through online investment platforms that support IPO applications. Applicants are required to select the relevant category, enter the bid details as per the issue terms, and confirm the mandate for blocking funds. Once submitted, the application remains subject to allotment as per regulatory procedures and disclosed timelines.
For more details, visit the KRM Ayurveda Limited IPO page.
Details | Information |
IPO Date | January 19, 2026 to January 21, 2026 |
Issue Size | 57,40,000 shares (agg. up to ₹77 Cr) |
Price Band | ₹128 to ₹135 per share |
Lot Size | 1000 shares |
Listing At | NSE, SME |
Capital Expenditure for Construction and Development of Telemedicine Operational Facilities
Purchase of CRM Software and Hardware Infrastructure
Human Resources
Repayment/Prepayment of loan
To meet the Working Capital requirements of the Company
General Corporate Purposes
Event | Date |
|---|---|
IPO Open Date | Mon, Jan 19, 2026 |
IPO Close Date | Wed, Jan 21, 2026 |
Tentative Allotment | Thu, Jan 22, 2026 |
Initiation of Refunds | Fri, Jan 23, 2026 |
Credit of Shares to Demat | Fri, Jan 23, 2026 |
Tentative Listing Date | Tue, Jan 27, 2026 |
Cut-off time for UPI mandate confirmation | 5 PM on Wed, Jan 21, 2026 |
₹128 to ₹135 per share
Minimum Lot Size and Application Details
Application | Lots | Shares | Amount |
Individual investors (Retail) (Min) | 2 | 2,000 | ₹2,70,000 |
Individual investors (Retail) (Max) | 2 | 2,000 | ₹2,70,000 |
S-HNI (Min) | 3 | 3,000 | ₹4,05,000 |
S-HNI (Max) | 7 | 7,000 | ₹9,45,000 |
B-HNI (Min) | 8 | 8,000 | ₹10,80,000 |
The KRM Ayurveda Limited IPO application process can be completed online through your trading platform. Below is a step-by-step guide to applying for the IPO:
Access your trading account using the broker's app or website.
Go to the IPO section to view active IPO listings.
Locate KRM Ayurveda Limited IPO in the list of available IPOs and click the ‘Apply’ button.
Specify the number of shares (lot size: 1000 shares) within the price band of ₹128 to ₹135 per share.
Enter your UPI ID for payment authorisation and ensure sufficient funds in your bank account.
Review your application details and confirm the UPI mandate before 5 PM on the last application day.
Submit the application and monitor the allotment status to check if shares have been allocated to you.
The allocation of shares in the KRM Ayurveda IPO is structured across investor categories in line with applicable regulatory requirements. The issue provides defined reservations for qualified institutional buyers, non-institutional investors, and retail individual investors, with each category allotted a specified proportion of the net issue. This allocation framework outlines how the shares offered are distributed among different classes of investors.
Investor Category | Shares Offered |
QIB Shares Offered | Not more than 50% of the Net Issue |
Retail Shares Offered | Not less than 35% of the Net Issue |
NII Shares Offered | Not less than 15% of the Net Issue |
This reservation structure reflects the categorisation and allocation approach disclosed for the issue, indicating the proportion of shares available to each investor segment.
Total Assets: Grew from ₹39.48 crore in FY23 to ₹66.79 crore as of March 2025.
Total income: Stood at ₹76.95 crore in FY25, as compared to ₹89.38 crore in FY23.
Profit After Tax (PAT): Stood at ₹12.10 crore for March 2025 as compared to ₹7.60 crore in FY23.
Net Worth: Recorded at ₹23.88 crore in FY25 in comparison to ₹8.37 crore in FY23.
Reserves and surplus: Stood at ₹23.73 crore in FY25, as compared to ₹8.22 crore in FY23.
EBITDA: Stood at ₹19.11 crore in March 2025 in comparison to ₹11.03 crore in FY23.
The company’s asset base has expanded over the review period, indicating a broader operational scale and increased balance sheet size.
Total income in the most recent period reflects a moderation compared to an earlier year, suggesting changes in revenue composition or business activity levels.
Profit after tax has shown an upward movement over time, reflecting an improvement in post-expense earnings during the period under review.
Net worth has strengthened compared to earlier years, supported by internal accruals and retained earnings.
Reserves and surplus have increased, indicating accumulation of profits within the business rather than distribution.
Operating performance, as reflected at the earnings-before-depreciation-and-tax level, has improved over the period, pointing to better operating outcomes.
Overall, recent performance reflects a phase of balance sheet expansion alongside changes in income trends, with internal financial strengthening contributing to the company’s current position.
The company operates in the AYUSH healthcare segment, where demand patterns, regulatory frameworks, and patient preferences may vary across regions, which can influence operational consistency.
A portion of the business is dependent on specialised healthcare services and teleconsultation models, where execution challenges, compliance requirements, or operational integration issues may affect outcomes.
KRM Ayurveda Ltd. has an established presence across hospitals, clinics, product manufacturing, and teleconsultation services, which provides multiple channels for service delivery within the traditional healthcare ecosystem.
The stated use of IPO proceeds towards infrastructure development, technology systems, human resources, and working capital reflects a focus on strengthening existing operations and supporting organised business expansion.
KPI | Mar 31, 2025 |
ROE | 67.86% |
ROCE | 43.33% |
Debt/Equity | 1.31 |
RoNW | 67.86% |
PAT Margin | 15.80% |
EBITDA Margin | 24.96% |
Price to Book Value | 0.08 |
Registrar | Lead Manager(s) |
|---|---|
Skyline Financial Services Pvt.Ltd. | NEXGEN Financial Solutions Pvt. Ltd. |
KRM Ayurveda Ltd. A-16 G T Karnal road North West Delhi, New Delhi, 110033
Phone: +91- 9289101700
Email: compliance@krmayurveda.com
Website: http://www.krmayurvedaindia.com/
KRM Ayurveda Ltd. operates in the AYUSH healthcare segment through hospitals, clinics, teleconsultation services, and Ayurvedic product manufacturing. Since its incorporation in 2019, the company has expanded its treatment scope beyond kidney-related care to include other chronic and lifestyle-related health conditions, supported by physical facilities and remote service channels.
The IPO outlines the company’s business profile, issue structure, objectives, and application process in line with regulatory disclosures. Investors may apply through ASBA-enabled bank accounts or eligible online platforms, subject to the prescribed procedures and timelines. All applications remain subject to allotment as per applicable regulations and issue terms.
Interested in more opportunities? Check out our Upcoming IPO section for new listings and don’t forget to check your KRM Ayurveda IPO allotment status.
No result found
The Managing Director and Promoter of KRM Ayurveda Ltd. is Dr. Puneet Dhawan.
The KRM Ayurveda IPO is scheduled to open for subscription on January 19, 2026, and will close on January 21, 2026, as per the disclosed issue timeline.
The company’s core business includes operating hospitals and clinics in the AYUSH healthcare segment, providing teleconsultation services, and manufacturing Ayurvedic and herbal products. The sustainability of its business model depends on factors such as regulatory developments, operational execution, demand for traditional healthcare services, and the company’s ability to manage its facilities and distribution channels over time.
The IPO comprises an issue of 57,40,000 equity shares, aggregating to an issue size of up to ₹77 crore, based on the disclosed price band.
‘Pre-apply’ generally refers to the facility offered by some platforms that allows investors to submit IPO applications before the official opening date, with final confirmation required once the issue opens. The availability and process of this facility depend on the platform used.
The lot size for the KRM Ayurveda IPO is 1,000 equity shares. The minimum application for retail investors requires applying for two lots, subject to the terms stated in the offer.
The tentative allotment date for the KRM Ayurveda IPO is January 22, 2026, as per the disclosed schedule.
Skyline Financial Services Pvt. Ltd. has been appointed as the registrar to the issue for the KRM Ayurveda IPO.
There are no publicly stated governance issues or red flags highlighted. Investors may review the offer documents, including sections on management, board composition, and risk factors, for detailed and verified disclosures.
Investors can apply for the IPO through the ASBA facility using a bank account linked to a demat account via net banking or through eligible online platforms. The process involves selecting the IPO, entering bid details within the prescribed price band, and confirming the fund-blocking mandate within the stipulated timeline.
Yes, a valid demat account is required to apply for the KRM Ayurveda IPO, as equity shares are allotted and held only in dematerialised form.
Investors can check the allotment status after the allotment date through the registrar’s website or the stock exchange platform. In case of allotment, shares are credited to the demat account, while funds are unblocked or refunded if shares are not allotted.
Disclaimer :
The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes. The securities are quoted as an example and not as a recommendation. Past performance is not necessarily a guide to future performance.
The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.
Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.
BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.
Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
For more disclaimer, check here : https://www.bajajbroking.in/disclaimer
Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading